Hydrochloorthiazide and Hypernatriaemie

Not Applicable

Completed

• Conditions: Hypernatraemia
• Interventions: Drug: Hydrochloorthiazide; Drug: placebo

• Registration Number: NCT01974739
• Lead Sponsor: Medical Centre Leeuwarden

Brief Summary

Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-10-28
• Study First Submitted QC: 2013-10-28
• Study First Posted: 2013-11-03
• Primary Completion: 2015-05
• Study Completion: 2015-05
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-22
• Last Update Posted: 2015-06-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• sodium > 142

Exclusion Criteria

• no informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
hydrochloorthiazide	Hydrochloorthiazide	once a day 25 mg
placebo	placebo	once a day placebo

Primary Outcome Measures

Name	Time	Method
sodium level	7 days	a decrease of 5 mmol/L sodium in plama

Secondary Outcome Measures

Name	Time	Method
time hypernatraemia	7 days	decrease of duration high sodium level in plasma

Trial Locations

Locations (1)

Medical Centre Leeuwarden; 🇳🇱 Leeuwarden, Friesland, Netherlands